Valiolamine derivatives as glucosidase inhibitors

A compound according to Formula (I):

• or a pharmaceutically acceptable salt thereof,
• wherein
• W1-W5 are each independently selected from the group consisting of —H, benzyl, —C(═O)—C1-C9 alkyl, and —C(═O)O—C1-C9 alkyl;
• R1 is optionally substituted C1-C9 alkylene;
• R2 is absent or selected from the group consisting of —NH—, —O—, —C(═O)—, and —NH—C(═O)O—;
• R3 is absent or selected from the group consisting of —O—, —C(═O)—, —C(═O)O, and optionally substituted C1-C6 alkylene;
• R4 is —NH—;
• R5 is
• wherein
• X1, X2, X3, X4, and X5 are each independently selected from the group consisting of —H, —NO2, —N3, optionally substituted C2-C12 heterocycle, and optionally substituted C1-C12 heteroaryl.